Document is current

Article History

Accepted: 23 February 2021

First Online: 12 March 2021

Compliance with ethical standards

:

: BMKB served as the PI of research grants to Massachusetts General Hospital from Novo Nordisk, OPKO, Novartis, and Strongbridge; and consults occasionally for Aeterna Zentaris, Ascendis, EMD Serono, Novo Nordisk, Pfizer, and Strongbridge. CH was a NordiNet® IOS investigator and has received lecture fees from Novo Nordisk, Pfizer and Sandoz, and is a member of the global steering committee for the PATRO study (Sandoz) and has consulted for Novo Nordisk and Ascendis. PC has received honoraria for participation in advisory boards for Shire, Pfizer, and Novo Nordisk. MBG reports research support from Camurus, Chiasma, Corcept, Crinetics, Ipsen, Novartis, Novo Nordisk, Opko, Pfizer, Strongbridge, and Teva; and has been a scientific consultant to Chiasma, Ipsen, and Novo Nordisk. ACB, and NN are employees of Novo Nordisk. NK is an employee of Novo Nordisk and has stocks in Novo Nordisk and Pfizer. MMW has received honoraria for participation in advisory boards and as a speaker from Novartis, Ipsen and Novo Nordisk, and research grants from Ipsen and Novartis.

: Both studies were conducted with approval from relevant ethics committees, written consent from patients, and pseudonymization of all data in accordance with the Declaration of Helsinki, Guideline for Good Pharmacoepidemiology Practices, and regulatory requirements.

: Written consent was obtained from patients for the two original studies.

: These data were previously presented in poster form at the virtual 22nd European Congress of Endocrinology (eECE), 5–9 September, 2020.